Callan JMB Inc. has entered into a strategic teaming agreement with Biostax Corp, operating as Attune Biotech Inc., a clinical-stage biopharmaceutical company. The partnership is expected to generate approximately $50 to $75 million in total combined revenue over the next five years, with revenue shared through a profit-sharing platform structured at either 50% or 60%, depending on the contract and scope. Under the agreement, Callan JMB will serve as an independent third-party overseer of Attune's manufacturing, quality assurance, and deployment operations, leveraging its federal contract experience, cold chain infrastructure, and strategic national stockpile relationships. The agreement positions Attune’s therapeutic pipeline for immediate federal deployment through Callan JMB’s existing government infrastructure, and represents a potential revenue opportunity of $25 million to $45 million for Callan JMB over five years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Callan JMB Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9626143) on January 15, 2026, and is solely responsible for the information contained therein.